Group 1 - BeOne Medicines Ltd. (NASDAQ:ONC) is recognized as one of the best-performing European stocks, particularly following the successful Phase 1/2 trial of sonrotoclax for patients with relapsed or refractory mantle cell lymphoma [1][2] - The trial demonstrated clinically relevant responses in extensively pretreated patients, with promising outcomes for secondary goals such as progression-free survival, response duration, and complete response rate [2] - The company plans to submit data for potential approval to the U.S. Food and Drug Administration and other international regulatory agencies, having already filed new drug applications in China for sonrotoclax targeting chronic lymphocytic leukemia and relapsed or refractory mantle cell lymphoma [3] Group 2 - BeOne Medicines Ltd. specializes in oncology medicines, focusing on blood cancers and solid tumors [4] - While the potential of ONC as an investment is acknowledged, there are suggestions that certain AI stocks may offer greater upside potential with less downside risk [4]